oligometastatic renal cell carcinoma.
Conditions
Interventions
Experimental group:Axitinib + Toripalimab + Selective Tumor Embolization +/- Cytoreductive Nephrectomy
Sponsors
Tianjin Cancer Hospital Airport Hospita
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–80 years. 2. Pathologically confirmed diagnosis of clear cell or non-clear cell renal cell carcinoma. 3. Imaging findings indicate =5 metastatic lesions. 4. ECOG performance status score of 0 or 1. 5. Expected survival time exceeding 6 months. 6. Patient voluntarily provided signed informed consent.
Exclusion criteria
Exclusion criteria: 1. History of or concurrent other malignant tumors. 2. Severe impairment in cardiac, pulmonary, hepatic, or renal function, or inability to tolerate the study treatment. 3. Patients with brain metastases, bone marrow metastases, or an extremely poor prognosis. 4. History of severe allergic reactions to immunotherapy or targeted agents. 5. Pregnant or lactating women.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Progression-Free Survival;Serious Adverse Events; | — |
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Countries
China
Contacts
Public ContactQing Yang
Tianjin Cancer Hospital Airport Hospita
Outcome results
None listed